Paul D. Rennert (@pdrennert) 's Twitter Profile
Paul D. Rennert

@pdrennert

Co-founder, President & CSO, Aleta Biotherapeutics, aletabio.com - Founder & Principal, SugarCone Biotech, commentary at sugarconebiotech.com

ID: 1001726569

linkhttp://www.aletabio.com calendar_today10-12-2012 13:57:28

20,20K Tweet

6,6K Followers

405 Following

Paul D. Rennert (@pdrennert) 's Twitter Profile Photo

Notable paper: immune signatures in CRC identifying overlapping features associated with good patient prognosis including tertiary lymphoid organs, specialized endothelial cells (HEV), T and B cell signatures and IL15. Also looks at immunosuppression. nature.com/articles/s4301…

Paul D. Rennert (@pdrennert) 's Twitter Profile Photo

Folks to see the actual impact of IRA price cuts you need to compare to prices minus rebates as detailed here and published: jmcp.org/doi/10.18553/j…

Folks to see the actual impact of IRA price cuts you need to compare to prices minus rebates as detailed here and published: jmcp.org/doi/10.18553/j…
Paul D. Rennert (@pdrennert) 's Twitter Profile Photo

Table from ApexOnco #ASCO24 CAR-GPC3 for HCC coverage. >But no new data from CARsGen CT0801. >AbleZeta excluded patients with active HBV or HCV while CARsGen specifically enrolled HCV+ patients. >R other CARs segregating by HCC cause (viral v metabolic)? >any new CT0801 data?

Table from <a href="/ApexOnco/">ApexOnco</a> #ASCO24 CAR-GPC3 for HCC coverage. 
&gt;But no new data from CARsGen CT0801. 
&gt;AbleZeta excluded patients with active HBV or HCV while CARsGen specifically enrolled HCV+ patients. 
&gt;R other CARs segregating by HCC cause (viral v metabolic)?
&gt;any new CT0801 data?
Genetic Engineering & Biotechnology News (@genbio) 's Twitter Profile Photo

Hold and Kill: Halda Raises $126M toward Precision Cancer Treatments Craig Crews-founded startup eyes 2025 trial for lead candidate, based on regulated induced proximity targeting chimeras (RIPTAC™) platform. Learn more: hubs.li/Q02LFvdk0

AACR (@aacr) 's Twitter Profile Photo

The U.S. FDA approved the targeted therapy lazertinib in combination with the bispecific antibody amivantamab-vmjw for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with certain EGFR mutations: bit.ly/3yJtGMm

Paul D. Rennert (@pdrennert) 's Twitter Profile Photo

Xencor has terminated developed of IL-12-Fc, a reduced potency cytokine fusion protein. #XmAb662 had been in a solid tumor basket study with #pembrolizumab. $XNCR clinicaltrials.gov/study/NCT05996…

Paul D. Rennert (@pdrennert) 's Twitter Profile Photo

VEGF is one of the three big sticks to pair with PD-1 inhibitors to beat cancer. The other two, so far poorly used, are TGFbeta and beta-catenin. Degraders will be useful here.